SEC Filing Summary: ARCA biopharma, Inc. Form 10-Q
Important identity mismatch: The request names Oruka Therapeutics, Inc., but the supplied filing is for ARCA biopharma, Inc. (Nasdaq: ABIO), for the quarter ended March 31, 2021. This summary reflects the filing provided, not an Oruka filing.
Business context and reporting period
ARCA describes itself as a clinical-stage biopharmaceutical company developing targeted therapies. Its lead candidates are rNAPc2 (AB201), being studied for hospitalized COVID-19 patients, and Gencaro (bucindolol) for atrial fibrillation in selected heart-failure patients. The company reported no revenue to date.
Financial results and liquidity
| Metric | Q1 2021 | Q1 2020 / comparison |
|---|---|---|
| Revenue | None to date | None to date |
| Research and development expense | $2.876 million | $0.365 million |
| General and administrative expense | $1.226 million | $0.975 million |
| Total costs and expenses | $4.102 million | $1.340 million |
| Net loss | $4.100 million | $1.320 million |
| Net loss per share, basic and diluted | $0.33 | $0.83 |
| Net cash used in operating activities | $5.225 million | $1.686 million |
| Cash and cash equivalents | $66.933 million at March 31, 2021 | $49.071 million at December 31, 2020 |
- Cash rose by $17.862 million in the quarter, mainly from $23.093 million of net financing proceeds, offset by operating cash use and capital purchases.
- Current assets were $68.730 million and current liabilities $2.880 million, implying working capital of approximately $65.850 million. Total liabilities were $3.274 million, including operating lease liabilities; the filing reports no interest expense in Q1 2021.
- Stockholders’ equity was $65.909 million. Shares outstanding increased from 9,548,150 at year-end 2020 to 14,410,143 at March 31, 2021, reflecting equity issuance.
- Margins are not meaningful because the company had no revenue. Management estimated that March 31 cash would fund operations through the end of fiscal 2022, but said Phase 3 trials would likely require additional financing.
Material changes versus the prior comparable period
- R&D expense increased $2.511 million year over year. Management attributed the increase principally to higher clinical expenses and manufacturing-process development costs associated with the rNAPc2 program, as well as higher outside services and personnel costs.
- G&A expense increased $0.251 million, primarily due to higher personnel costs.
- Net loss increased $2.780 million and operating cash use increased $3.539 million year over year.
- Q1 2021 financing provided $23.093 million, while the comparable 2020 quarter had no financing cash inflow. The quarter’s share issuance was under the at-the-market equity program.
Outlook, risks, and other notable items
- ARCA was enrolling patients in the approximately 100-patient Phase 2b ASPEN-COVID-19 rNAPc2 trial and expected topline data in Q3 2021. Timing and development plans depended on enrollment, results, FDA guidance, and drug supply. A planned Phase 3 program would require additional funding.
- PRECISION-AF, the planned Phase 3 Gencaro trial, was on hold amid the pandemic and the company’s prioritization of rNAPc2. Initiation depended on additional financing and improved conditions for recruiting cardiovascular-trial patients.
- ARCA said it was pursuing partnering, co-development, and other strategic opportunities. It warned that failure to obtain sufficient capital or complete a strategic transaction could force it to delay, reduce, or discontinue development or operations. Further equity financing could materially dilute shareholders.
- The company reported no products approved for commercial sale and no product revenue. Principal risks include clinical and regulatory failure or delay, enrollment and manufacturing issues, dependence on third parties, competition, financing availability, and Nasdaq listing compliance.
- The filing says the financial statements were prepared on a going-concern basis and describes uncertainty around future capital needs, while also stating that existing cash was expected to support operations through FY2022.
- Management reported disclosure controls and procedures were effective at a reasonable level of assurance, with no material change in internal control over financial reporting during the quarter. The filing reported no legal proceedings.
- After quarter-end, the company amended its ATM agreement in April 2021 and reported $50 million available under the offering. The filing also notes a May 2021 employment agreement and option grant for C. Jeff Dekker.
Important facts for investors to verify
- Confirm the issuer and ticker: this supplied 10-Q is for ARCA biopharma (ABIO), not Oruka Therapeutics.
- Check subsequent disclosures for ASPEN-COVID-19 enrollment, Q3 2021 data timing, results, and any Phase 3 plans or financing requirements.
- Verify the amount and terms of subsequent ATM share sales, remaining offering capacity, and resulting dilution.
- Assess whether cash runway assumptions remain valid, particularly given trial costs and the stated need for funding for Phase 3 programs.
- Review subsequent updates on PRECISION-AF, Gencaro financing and partnering, and the company’s ability to maintain its Nasdaq listing.